FDA Probes How To Compile Clinical Trial Data; Legal, Scientific Barriers Remain
Executive Summary
Despite having gathered large amounts of clinical trial data through the years, FDA faces challenges when it comes to analyzing the data outside of the original scope in which it was collected
You may also be interested in...
Changes To Antidepressant Black Box On Suicide Recommended By FDA Panel
FDA's findings that the suicidality risk with antidepressants does not extend beyond young adults should be added to the current "black box" warning on pediatric suicidality, the Psychopharmacologic Drugs Advisory Committee says
FDA Disease Models Will Focus On Areas With Poor R&D Track Records
FDA's disease state modeling efforts may focus on therapeutic areas which traditionally have suboptimal drug development, Office of Clinical Pharmacology & Biopharmaceutics Director Larry Lesko said
Pharmacogenomics Guidance Cites Benefits Of Voluntary Submissions
FDA's final pharmacogenomics guidance outlines the benefits of voluntary pharmaceutical industry submissions of genomic data to the agency